<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131767</url>
  </required_header>
  <id_info>
    <org_study_id>398/04</org_study_id>
    <nct_id>NCT01131767</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Naproxen Sodium 220 mg &amp; Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fed Conditions</brief_title>
  <official_title>A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Naproxen Sodium 220 mg + Pseudoephedrine HCL 120 mg ER Tablets and Aleve Cold and Sinus® Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the bioequivalence of Naproxen sodium 220 mg +
      Pseudoephedrine Hydrochloride 120 mg Extended Release tablets of with Aleve Cold and Sinus in
      healthy adult human subjects, under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open randomized, two treatment, two period, two sequence, single dose, crossover study of 26
      healthy human adult subjects under fed conditions with a washout period of 27 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Naproxen Sodium &amp; Pseudoephedrine HCl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aleve Cold and Sinus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen Sodium &amp; Pseudoephedrine HCl</intervention_name>
    <description>Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets</description>
    <arm_group_label>Naproxen Sodium &amp; Pseudoephedrine HCl</arm_group_label>
    <arm_group_label>Aleve Cold and Sinus</arm_group_label>
    <other_name>Aleve Cold and Sinus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must fulfill all of the following criteria to be considered for inclusion into
        this study:

          -  Subjects will provide written informed consent.

          -  Subjects must be healthy human beings within 18-45 years of age (inclusive) weighing
             at least 50 kg.

          -  Subjects must be within ±15% of ideal body weight in relation to height according to
             Life Insurance Corporation of India height-weight chart for non- medical cases.

          -  Subjects must be of normal health as determined by medical history and physical
             examination performed within 21 days prior to the commencement of the study.

          -  Have normal ECG, X-ray and vital signs.

          -  Availability of subject for the entire study period and willingness to adhere to
             protocol requirements as evidenced by written informed consent.

        If subject is a female volunteer and

          -  Is of child bearing potential practicing an acceptable method of birth control for the
             duration of the study as judged by the investigator(s), such as condoms, foams,
             jellies. diaphragm,intrauterine device (IUD), or abstinence.

          -  Is postmenopausal for at least 1 year.

          -  Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
             hysterectomy has been performed on the subject.

        Exclusion Criteria:

        The subjects will be excluded under following conditions:

        History or presence of significant:

          -  Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal,
             endocrine,immunologic, dermatologic, musculoskeletal, neurological or psychiatric
             disease.

          -  Alcohol dependence, alcohol abuse or drug abuse within past one year.

          -  Moderate to heavy smoking (&gt;10 cigarettes/day) or consumption of tobacco products.

          -  Asthma, urticaria or other allergic type reactions after taking any medication.

        Subjects who through completion of the study, would have donated in excess of

          -  500 ml of blood in 14 days, or

          -  500 - 800ml of blood in 14 days (unless approved by the Principal Investigator)

          -  1000 ml of blood in 90 days

          -  1250 ml of blood in 120 days

          -  1500 ml of blood in 180 days

          -  2000 ml of blood in 270 days

          -  2500 ml of blood in 1 year

        Subjects who have participated in another clinical trial within 3 months of study start.

        Subjects who have:

          -  Systolic blood pressure less than 90 mm of Hg and higher than 150 mm of Hg

          -  Diastolic blood pressure less than 60 mm of Hg and more than 95 mm of Hg. Minor
             deviations (1-3 mm Hg) at check-in may be acceptable at the discretion of the
             physician/investigator.

          -  Pulse rate below 50/min. and above 105/min. Female volunteers demonstrating a positive
             pregnancy screen or currently breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandhya Ravi, MBBS, MS.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lotus Labs Pvt. Ltd.,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lotus Labs Private Limited</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>June 11, 2010</last_update_submitted>
  <last_update_submitted_qc>June 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>M.S. Mohan / Vice President, R&amp;D</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Crossover</keyword>
  <keyword>Naproxen Sodium and Pseudoephedrine Hydrochloride</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

